Related Experiment Video

Updated: Jun 1, 2026

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
08:17

A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research

Published on: August 15, 2019

Clinical development of panobinostat in classical Hodgkin's lymphoma

Yasuhiro Oki1, Amanda Copeland, Anas Younes

  • 1Department of Lymphoma/Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

Expert Review of Hematology
|June 15, 2011
PubMed

Insights

Panobinostat, a deacetylase (DAC) inhibitor, shows promise for treating relapsed classical Hodgkin's lymphoma (cHL). A Phase II study demonstrated significant tumor reduction and remissions in patients receiving this novel anticancer therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Deacetylase (DAC) inhibitors represent a novel class of anticancer agents with multifaceted mechanisms of action.
  • Panobinostat, a potent DAC inhibitor, exhibits significant in vitro antiproliferative effects against classical Hodgkin's lymphoma (cHL) cells.
  • Early Phase I studies indicated promising clinical activity for panobinostat in relapsed cHL patients.

Purpose of the Study:

  • To review the current development status of panobinostat as a treatment for relapsed classical Hodgkin's lymphoma (cHL).
  • To compare the efficacy of panobinostat with other DAC inhibitors in the context of relapsed cHL.
  • To discuss future research directions for optimizing panobinostat therapy.

Main Methods:

  • Review of existing clinical trial data for panobinostat in relapsed cHL.
  • Comparative analysis of panobinostat's activity against other DAC inhibitors.
  • Discussion of potential combination therapies and predictive marker identification.

Main Results:

  • A large Phase II study in relapsed cHL patients showed panobinostat reduced tumor measurements in 74% of participants.
  • The Phase II study reported 23% partial remissions and 4% complete remissions with panobinostat treatment.
  • Panobinostat demonstrated significant in vitro antiproliferative activity against cHL cell lines.

Conclusions:

  • Panobinostat exhibits notable clinical activity in patients with relapsed classical Hodgkin's lymphoma.
  • Further research should explore combination regimens and predictive biomarkers to enhance patient selection and treatment outcomes.
  • Panobinostat is a promising therapeutic option for relapsed cHL, warranting continued investigation.

More Related Videos

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...